Key statistics
On Thursday, Summit Therapeutics Inc (SMMT:NMQ) closed at 24.55, -33.49% below its 52-week high of 36.91, set on Apr 24, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.00 |
---|---|
High | 25.94 |
Low | 20.49 |
Bid | 24.38 |
Offer | 24.40 |
Previous close | 22.62 |
Average volume | 4.77m |
---|---|
Shares outstanding | 742.67m |
Free float | 115.30m |
P/E (TTM) | -- |
Market cap | 18.23bn USD |
EPS (TTM) | -0.3309 USD |
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
More ▼
- Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
- Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
- Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
- Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
- Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
More ▼